Chicago-Watchful waiting is a common approach to prostate cancer, especially in patients who are in the later years of their life. A certain percentage of these men will wait, change their minds, and seek intervention. Extensive research efforts have been devoted to identifying predictors of outcomes after treatment with surgery or radiation therapy, but little is known about the outcome of watchful waiting during the PSA era.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Drug extends survival in prostate cancer with genetic mutations
December 8th 2023“Our analysis suggests that there is superior clinical benefit with olaparib versus control both in patients who had and had not received previous taxane treatment,” said Maha Hussain, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University.